Who are low dose peroral misoprostol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): preoperative vaginal misoprostol, Misoprostol 400 Microgram Oral Tablet, misoprostol and cervical ripening, Intrauterine Misoprostol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-peroral-misoprostol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

low dose peroral misoprostol — Competitive Intelligence Brief

low dose peroral misoprostol (low dose peroral misoprostol) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin E1 analogue. Area: Gastroenterology.

marketed Prostaglandin E1 analogue Prostaglandin E receptor (EP receptor) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

low dose peroral misoprostol (low dose peroral misoprostol) — University Medical Centre Ljubljana. Misoprostol is a prostaglandin E1 analogue that stimulates gastric mucus secretion and reduces gastric acid production to protect the gastrointestinal mucosa.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
low dose peroral misoprostol TARGET	low dose peroral misoprostol	University Medical Centre Ljubljana	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
preoperative vaginal misoprostol	preoperative vaginal misoprostol	Ain Shams Maternity Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
Misoprostol 400 Microgram Oral Tablet	Misoprostol 400 Microgram Oral Tablet	Assuta Ashdod Hospital	marketed	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)
misoprostol and cervical ripening	misoprostol and cervical ripening	Ullevaal University Hospital	phase 3	Prostaglandin E1 analogue	Prostaglandin E receptor (EP1, EP3)
Intrauterine Misoprostol	Intrauterine Misoprostol	Department of Medical Services Ministry of Public Health of Thailand	phase 3	Prostaglandin E1 analogue	Prostaglandin E receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin E1 analogue class)

Ain Shams Maternity Hospital · 1 drug in this class
Assuta Ashdod Hospital · 1 drug in this class
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class
Ullevaal University Hospital · 1 drug in this class
University Medical Centre Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low dose peroral misoprostol — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-peroral-misoprostol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab